Navigation Links
OrbusNeich's Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
Date:5/15/2012

weeks," said Prof. Landmesser. "The data will be presented at a conference later this year."

About the Genous Technology

Genous is OrbusNeich's patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients that are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neointimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
2. Combo method reveals cells signal systems
3. Computer-designed molecules point to new therapy for cystic fibrosis
4. Radiotherapy Clinics of Georgias Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award
5. Valkee and University of Oulu Publish the First Clinical Trial on Bright Light Therapy Channeled via ear Canals in Seasonal Depression
6. Cell Therapy - Technologies, Markets and Companies
7. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
8. Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs
9. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... water with ultrasound and they,ll spin around their long ... knows exactly. But researchers at the National Institute of ... fast. At up to 150,000 revolutions per minute, these ... submerged in liquid ever reported. , The discovery of ... they could be used not only for moving around ...
(Date:7/22/2014)... CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer ... cosmetics, and other markets, announced today that it has ... qualified private investors led by Novit L.P., an investment ... transaction involved the signing of a Securities Purchase Agreement ... Stock at a price per share of $1.00, resulting ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Two new ... Board of Directors at its annual Shareholders Meeting on ... Information Officer of The PFM Group, and Stephen T. ... Center also announced the election of Michael A. DiPiano, ... Vice Chair and Richard P. Jaffe, Esq., of Duane ...
(Date:7/22/2014)... Massachusetts e SHENZHEN , ... Co., LTD, (BGI Tech), una filiale di BGI, la ... lancio mondiale di un nuovo servizio di sequenziamento dell,intero ... di Complete Genomics. Complete Genomics, molto ... tecnologie di sequenziamento proprietarie con il 99.999% di precisione ...
Breaking Biology Technology:NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3Two New Members Elected to University City Science Center Board of Directors 2Two New Members Elected to University City Science Center Board of Directors 3BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2
... MOUNTAIN VIEW, Calif., Feb. 25 Alexza,Pharmaceuticals, ... that it has initiated,its first Phase 3 ... an inhalation product candidate being developed for ... schizophrenia or bipolar disorder. Alexza,believes the novel, ...
... t2cure, a clinical,stage biopharmaceutical company developing novel regenerative ... it has appointed,Dr. Petra Rueck Head of Clinical ... join our company", said Manfred Ruediger,CEO of t2cure. ... be of critical importance to t2cure as we ...
... SAN DIEGO, Feb. 25 Speid & Associates, ... is hosting,a six session Webinar series on diabetes ... and April. Speakers will include former Food and,Drug ... Lipicky, as,well as a distinguished list of other ...
Cached Biology Technology:Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations 2The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics 2
(Date:7/22/2014)... Institute of Standards and Technology (NIST), working with ... technique for analyzing biological cells and tissues based ... technique is an advanced form of the widely ... signals that are 10,000 times stronger than obtained ... than obtained from comparable "coherent Raman" instruments, and ...
(Date:7/22/2014)... commercial diet programs and pills, the Weight Watchers program ... the money. The Jenny Craig regimen generated the greatest ... tested, according to researchers at Duke-National University of Singapore ... the June issue of the journal Obesity , ... per dollar spent as insurance carriers consider coverage for ...
(Date:7/22/2014)... Nancy Buccola, MSN, APRN, PMHCNS-BC, CNE, Assistant Professor ... New Orleans School of Nursing, contributed samples used ... material associated with schizophrenia and also suggesting a ... The study, Biological insights from 108 schizophrenia-associated genetic ... Nature , available at http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13595.html., ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3LSUHSC contributes to work identifying new DNA regions associated with schizophrenia 2
... of an embryonic stem cell, which has the potential to ... complex interaction of genes, proteins that bind DNA, and molecules ... paper, biologists from MIT and the University of California at ... of stem cells into mature heart cells. The study, the ...
... ultrasound waves, MIT engineers have found a way to ... drug delivery more efficient. This technology could pave the ... to the researchers. "This could be used for ... systemic drugs and proteins such as insulin, as ...
... Alps that are not native to that region? Which ... How big a threat will they become to local ... today by the European Commission,s in-house science service, the ... answering these and other questions related to 16 000 ...
Cached Biology News:Probing matters of the heart 2Probing matters of the heart 3Getting (drugs) under your skin 2Getting (drugs) under your skin 3Environment: Pooling information to combat the threat of alien species in Europe 2Environment: Pooling information to combat the threat of alien species in Europe 3
... T Squareds patented high efficiency dynamic valve ... With the most compact, lightweight package in ... use in portable air and gas applications., ... high efficiency. , Includes DC Motor. ...
...
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
Biology Products: